- Home
- TDUP vs NUVB Comparison
TDUP vs NUVB Comparison
Compare TDUP & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TDUP
- NUVB
- Stock Information
- Founded
- TDUP 2009
- NUVB 2018
- Country
- TDUP United States
- NUVB United States
- Employees
- TDUP N/A
- NUVB N/A
- Industry
- TDUP Catalog/Specialty Distribution
- NUVB Biotechnology: Pharmaceutical Preparations
- Sector
- TDUP Consumer Discretionary
- NUVB Health Care
- Exchange
- TDUP Nasdaq
- NUVB Nasdaq
- Market Cap
- TDUP 1.3B
- NUVB 1.1B
- IPO Year
- TDUP 2021
- NUVB N/A
- Fundamental
- Price
- TDUP $8.89
- NUVB $3.70
- Analyst Decision
- TDUP Buy
- NUVB Strong Buy
- Analyst Count
- TDUP 3
- NUVB 7
- Target Price
- TDUP $12.50
- NUVB $8.43
- AVG Volume (30 Days)
- TDUP 2.0M
- NUVB 6.6M
- Earning Date
- TDUP 11-03-2025
- NUVB 11-05-2025
- Dividend Yield
- TDUP N/A
- NUVB N/A
- EPS Growth
- TDUP N/A
- NUVB N/A
- EPS
- TDUP N/A
- NUVB N/A
- Revenue
- TDUP $277,729,000.00
- NUVB $14,355,000.00
- Revenue This Year
- TDUP $17.99
- NUVB $291.13
- Revenue Next Year
- TDUP $9.68
- NUVB $332.00
- P/E Ratio
- TDUP N/A
- NUVB N/A
- Revenue Growth
- TDUP 20.14
- NUVB 900.35
- 52 Week Low
- TDUP $0.50
- NUVB $1.54
- 52 Week High
- TDUP $12.28
- NUVB $4.09
- Technical
- Relative Strength Index (RSI)
- TDUP 40.01
- NUVB 61.67
- Support Level
- TDUP $8.65
- NUVB $3.55
- Resistance Level
- TDUP $9.35
- NUVB $3.88
- Average True Range (ATR)
- TDUP 0.41
- NUVB 0.24
- MACD
- TDUP -0.05
- NUVB -0.00
- Stochastic Oscillator
- TDUP 21.36
- NUVB 73.30
About TDUP ThredUp Inc.
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app and RaaS partners. Geographically, the majority of the company's revenue is generated from United States.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.